Top Page
Hydrix Limited
(Sydney:HYD)
Hydrix Limited (HYD) vs. S&P 500 (SPY)
Hydrix Limited Business Overview & Revenue Model
Hydrix Limited Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 10.63M | 13.16M | 10.33M | 7.45M | 14.93M | Gross Profit |
| 9.81M | -638.73K | -3.31M | -6.46M | 569.70K | EBIT |
| -1.42M | -4.00M | -5.98M | -8.93M | -2.40M | EBITDA |
| -7.92M | 1.30M | -4.05M | -6.34M | -1.23M | Net Income Common Stockholders |
| -9.56M | -396.93K | -5.55M | -9.78M | -3.22M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 914.27K | 1.15M | 1.94M | 6.65M | 1.69M | Total Assets |
| 8.62M | 14.58M | 15.94M | 19.38M | 20.50M | Total Debt |
| 7.61M | 4.73M | 5.40M | 5.97M | 9.92M | Net Debt |
| 6.69M | 3.58M | 3.46M | -673.27K | 8.23M | Total Liabilities |
| 11.98M | 8.22M | 12.66M | 13.67M | 18.20M | Stockholders Equity |
| -3.36M | 6.35M | 3.28M | 5.71M | 2.30M |
| Cash Flow | Free Cash Flow | |||
| -1.91M | -3.32M | -6.75M | -3.35M | -1.37M | Operating Cash Flow |
| -1.89M | -3.12M | -6.58M | -2.86M | -1.32M | Investing Cash Flow |
| -53.43K | -209.71K | -306.65K | -641.56K | -1.07M | Financing Cash Flow |
| 1.71M | 2.54M | 2.18M | 8.46M | 3.84M |
Hydrix Limited Technical Analysis
Hydrix Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
59 Neutral | $10.74B | 10.21 | -6.69% | 3.04% | 7.44% | -10.92% | |
46 Neutral | AU$650.34M | ― | -112.97% | ― | ― | -84.82% | |
44 Neutral | AU$4.64M | ― | -637.73% | ― | -13.05% | -184.09% | |
39 Underperform | AU$126.15M | ― | -52.37% | ― | 471.29% | -4.58% | |
36 Underperform | $3.98M | ― | -119.28% | ― | ― | 64.10% | |
34 Underperform | $541.09M | ― | -133.28% | ― | 72.47% | 20.08% |
Hydrix Limited Corporate Events
Hydrix Limited announced the cessation of 11,250 securities due to the lapse of conditional rights, as the conditions for these securities were not met by the deadline of March 31, 2025. This announcement may impact the company’s capital structure and could have implications for its stakeholders, reflecting on the company’s strategic adjustments in managing its securities.
Hydrix Limited announced the cessation of 10,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.
Hydrix Limited announced the cessation of certain securities due to the lapse of conditional rights, as the conditions were not met. This cessation involves 3,150 options that were set to expire in June 2027, impacting the company’s issued capital and potentially affecting investor perceptions of its financial strategies.
Hydrix Limited reported consecutive profitable quarters for its services division, driven by improved margins, increased billable utilization, and reduced operating costs. The company achieved a 37% increase in contract sales orders, with significant contributions from international clients and cardiac monitoring products. The recent FDA clearance for Gyder Surgical’s Hip Navigation System underscores Hydrix’s expertise in medical device development and boosts its venture investments. The company anticipates continued sales momentum and revenue growth, supported by a robust sales pipeline and strategic international market engagements.
Hydrix Limited reported a decrease in revenue by 5.2% to $5,595,872 for the half-year ending December 2024, with a significant reduction in losses to $635,660 compared to the previous year’s $2,495,571. Despite the improved financial performance, the company does not plan to pay dividends, reflecting a strategic focus on reinvesting in its operations and future growth, which may impact stakeholders’ expectations regarding immediate returns.
Hydrix Limited announced that Gyder Surgical, a company within its Ventures portfolio, has secured FDA 510(k) clearance for its GYDER Hip System, marking a pivotal step towards commercialization in the U.S. market. This clearance not only underscores Hydrix’s expertise in medical product development but also boosts Gyder Surgical’s market prospects, particularly in the extensive U.S. market for hip replacement procedures, enhancing the investment value for Hydrix Ventures to $2.65 million.
Hydrix Limited reported consecutive profitable quarters for its Hydrix Services segment, driven by strong contract sales orders and reduced operating costs, which have substantially improved its cash operating position. The company anticipates future revenue growth supported by a robust sales pipeline, including potential revenues from future program stages across 15 clients. Hydrix Medical is also building its sales pipeline, with optimism about funding commitments for its remote cardiac patient monitoring product. The company’s strategic focus on international markets and cardiac medtech clients demonstrates its expanding global outreach and market positioning.